Epime 1gm Injection contains Cefepime, a fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is indicated for the treatment of severe bacterial infections including pneumonia, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and febrile neutropenia. Cefepime exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The drug demonstrates enhanced stability against beta-lactamases, making it effective against resistant strains such as Pseudomonas aeruginosa and Enterobacter species. Epime 1gm Injection is administered via intravenous or intramuscular routes, ensuring rapid systemic distribution. Dosage and duration of therapy should be guided by the severity of infection, renal function, and susceptibility of the causative organism. Common adverse effects include hypersensitivity reactions, gastrointestinal disturbances, and transient elevations in liver enzymes. Caution is advised in patients with a history of cephalosporin or penicillin allergy. Renal function monitoring is recommended during prolonged therapy to adjust dosing and prevent toxicity. Epime 1gm Injection should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize the development of antimicrobial resistance.